{"prompt": "['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', '10.7.', 'Provision of Study Results to Investigators, Posting of', 'Information on Publically Available Clinical Trials Registers', 'and Publication', 'Where required by applicable regulatory requirements, an investigator signatory will be', 'identified for the approval of the clinical study report. The investigator will be provided', 'reasonable access to statistical tables, figures, and relevant reports and will have the', 'opportunity to review the complete study results at a GSK site or other mutually-', 'agreeable location.', 'GSK will also provide the investigator with the full summary of the study results. The', 'investigator is encouraged to share the summary results with the study subjects, as', 'appropriate.', 'GSK will provide the investigator with the randomization codes for their site only after', 'completion of the full statistical analysis.', 'The procedures and timing for public disclosure of the results summary and for', 'development of a manuscript for publication will be in accordance with GSK Policy.', 'A manuscript will be progressed for publication in the scientific literature if the results', 'provide important scientific or medical knowledge.', '64']['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', '11.', 'REFERENCES', 'Bateman ED, Ferguson GT, Barnes N et al. Dual bronchodilation with QVA149 versus', 'single bronchodilation therapy: The SHINE study. Eur Respir J. 2013 Dec; 42:1484-94', 'Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD:', 'a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23:932-946.', 'Chen H, Yu KD, Xu GZ. Association between Variant Y402H in Age-Related Macular', 'Degeneration (AMD) Susceptibility Gene CFH and Treatment Response of AMD: A', 'Meta-Analysis. PloS ONE 2012; 7: e42464', 'Dahl R, Chung KF, Buhl R et al. Efficacy of a new once-daily long-acting inhaled \u00df2-', 'agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010, 65:473-479.', 'Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily', 'umeclindinium/vilanterol 62.5/25mcg in COPD. Respir Med 2013; 107: 1538-1546.', 'European Medicines Agency (EMA). Guidelines on clinical investigation of medicinal', 'productsin the treatment of chronic obstructive pulmonary disease (COPD).', 'EMA/CHMP/48353572, 2012.', 'Feldman G, Maltais F, Khindri S, et al. A randomized blinded study to evaluate the', 'efficacy and safety of umeclidinium 62.5g compared with tiotropium 18 g in patients', 'with COPD. International Journal of COPD 2016; 11: 719-730', 'Feldman G, Siler T, Prasad N et al. Efficacy and safety of indacaterol 150 g once-daily', 'in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010, 10:11.', 'Gimeno-Santos E, Frei A, Steurer-Stey C, et al. Determinants and outcomes of physical', 'activity in patients with COPD: a systematic review. Thorax 2014; 0:1-9', 'GlaxoSmithKlineDocument Number [RM2006/00835/09, Umeclidinium (GSK573719)', \"Investigator's Brochure. Report Date -Aug-2016. -\", 'GlaxoSmithKlineDocument Number RM2009/00437/07, Umeclidinium + Vilanterol', \"Investigator's Brochure. Report date AUG-2015\", 'GOLD. Global Initiative for Chronic Obstructive Lung Disease [GOLD]. Global Strategy', 'for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary', 'Disease. Last Updated 2015. http://www.goldcopd.org.', 'Gorin MB. Genetic insights into age-related macular degeneration: Controversies', 'addressing risk, causality, and therapeutics. Mol. Asp. Med. 2012; 33: 467-486.', 'Hatcher RA, Trussell J, Nelson AL, Cates W Jr, et al, editors. Contraceptive Technology.', '20th revised edition. New York: Ardent Media, 2011.', '65']['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', 'James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee', 'WM. Pharmacokinetics of Acetaminophen-Adduct in Adults with Acetaminophen', 'Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.', 'Jones, P., Harding, G., Berry, P., Wiklund, I., Chen, W-H., Leidy, N. Development and', 'first validation of the COPD Assessment Test (CAT) Eur Respir J, 2009; 34: 648-654', 'Jones, P., Harding, G., Wiklund, I., Berry, P., Tabberer, M., Yu, R., Leidy, N. Tests of', 'the Responsiveness of the Chronic Obstructive Pulmonary Disease (COPD) Assessment', 'Test (CAT) Following Acute Exacerbation and Pulmonary Rehabilitation Chest, 2012,', '142 134-140', 'Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, D\u00e9ny P, Gault E. Quantification', 'of Hepatitis Delta Virus RNA in Serum by Consensus Real-Time PCR Indicates', 'Different Patterns of Virological Response to Interferon Therapy in Chronically Infected', 'Patients. J Clin Microbiol. 2005;43(5):2363-2369.', 'Leidy NK, Sexton CC, Jones PW, Notte SM. et al. Measuring respiratory symptoms in', 'clinical trials of COPD: reliability and validity of a daily diary. Thorax 2014; 69:5 424-', '430', 'Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S. Standardizing', 'measurement of chronic obstructive pulmonary disease exacerbations. Reliability and', 'validity of a patient-reported diary. Am J Respir Crit Care Med 2011; 183:323-329', 'Mahler DA, Ward J, Fierro-Carrion G, et al. Development of self-administered versions', 'of modified baseline and transition dyspnea indexes in COPD. J COPD 2004; 165-172', 'Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea.', 'Contents, inter-observer agreement, and physiologic correlates of two new clinical', 'indexes. Chest 1984, 85: 751-758.', 'Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of', 'umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive', 'pulmonary disease: results of a 24-week, randomized, controlled trial. Respiratory', 'medicine. 014;108:1752-60.', 'Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, Riley JH. Effects of a', 'combination of umeclidinium/vilanterol on exercise endurance in patients with chronic', 'obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv', 'Respir Dis. 2014;8:169-81.', 'Meguro M, Barley EA, Spencer S et al. Development and validation of an improved', 'COPD-Specific Version of the St. George Respiratory Questionnaire. Chest.', '2007;132:456-463', 'Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright', 'P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R,', '66']\n\n###\n\n", "completion": "END"}